IGF1 and amyotrophic lateral sclerosis: All these trials showed no clear beneficial effect of IGF-1 on ALS progression, whereas a meta-analysis concluded that, considering the two RCTs using the same outcome measure [58, 60], a significant difference in favor of rhIGF-1 treatment was shown; however, the quality of the evidence from the two trials was low [61].